Is NTLA a good stock to buy? We came across a bullish thesis on Intellia Therapeutics, Inc. on Markman Capital Insight’s Substack. In this article, we will summarize the bulls’ thesis on NTLA. Intellia Therapeutics, Inc.’s share was trading at $16.61 as of June 29th.
Pressmaster/Shutterstock.com
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. NTLA is emerging as a leading player in the next generation of gene-editing therapies following the first successful Phase 3 trial of an in vivo CRISPR treatment, lonvoguran ziclumeran (lonvo-z), for hereditary angioedema (HAE).
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
A single infusion reduced HAE attacks by 87% versus placebo, rendered 62% of patients attack-free, produced no serious adverse events, and met all primary and secondary endpoints with strong statistical significance.
Unlike earlier ex vivo CRISPR therapies that require chemotherapy and cell extraction, lonvo-z edits genes directly inside the body using lipid nanoparticle delivery, marking a major technological milestone that could establish a reusable regulatory and commercial framework for future in vivo gene-editing therapies. Despite this breakthrough, the stock declined as investors remained focused on commercialization risks, including patient adoption, reimbursement, pricing negotiations, long-term safety monitoring, and competition from effective chronic therapies.
However, the company has already initiated a rolling Biologics License Application with a potential U.S. launch targeted for the first half of 2027, while the simpler outpatient administration of lonvo-z offers meaningful advantages over existing gene-editing approaches. Beyond HAE, Intellia possesses a broader platform opportunity through nex-z for transthyretin amyloidosis, a substantially larger market with an estimated 250,000 to 500,000 patients globally, alongside additional pipeline programs that could benefit from the validation of its delivery platform.
The thesis argues that the recent clinical success significantly de-risks the entire in vivo CRISPR platform, positioning Intellia alongside other industry leaders to capture long-term value as gene editing expands into larger indications. While commercial execution remains the key uncertainty, successful regulatory approval and broader platform adoption could establish Intellia as a multi-decade compounder with substantial upside as the gene-editing market matures.